Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison.
Saved in:
| Title: | Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison. |
|---|---|
| Authors: | Ständer S; Section Pruritus Medicine, Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany., Pinter A; Goethe-University Frankfurt Am Main, Frankfurt Am Main, Germany., Hougeir FG; Southeast Research Specialists, Douglasville, GA, USA., Guyot P; Sanofi, Gentilly, France., Xu Y; Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA., Praestgaard AH; Sanofi, Cambridge, MA, USA., Freemantle N; Institute of Clinical Trials and Methodology, University College London, London, UK., Rossi AB; Sanofi, Cambridge, MA, USA., Bégo-Le-Bagousse G; Sanofi, Gentilly, France., Wang Z; Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA., Noonan K; Sanofi, Cambridge, MA, USA., Bastian M; Sanofi, Frankfurt, Germany. mike.bastian@sanofi.com. |
| Source: | Dermatology and therapy [Dermatol Ther (Heidelb)] 2025 Sep; Vol. 15 (9), pp. 2537-2551. Date of Electronic Publication: 2025 Jul 11. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Springer Healthcare Communications Country of Publication: Switzerland NLM ID: 101590450 Publication Model: Print-Electronic Cited Medium: Print ISSN: 2193-8210 (Print) NLM ISO Abbreviation: Dermatol Ther (Heidelb) Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| FullText | Links: – Type: pdflink Text: Availability: 1 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 40646412 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Ständer+S%22">Ständer S</searchLink>; Section Pruritus Medicine, Department of Dermatology and Center for Chronic Pruritus, University Hospital Münster, Münster, Germany.<br /><searchLink fieldCode="AU" term="%22Pinter+A%22">Pinter A</searchLink>; Goethe-University Frankfurt Am Main, Frankfurt Am Main, Germany.<br /><searchLink fieldCode="AU" term="%22Hougeir+FG%22">Hougeir FG</searchLink>; Southeast Research Specialists, Douglasville, GA, USA.<br /><searchLink fieldCode="AU" term="%22Guyot+P%22">Guyot P</searchLink>; Sanofi, Gentilly, France.<br /><searchLink fieldCode="AU" term="%22Xu+Y%22">Xu Y</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Praestgaard+AH%22">Praestgaard AH</searchLink>; Sanofi, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Freemantle+N%22">Freemantle N</searchLink>; Institute of Clinical Trials and Methodology, University College London, London, UK.<br /><searchLink fieldCode="AU" term="%22Rossi+AB%22">Rossi AB</searchLink>; Sanofi, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Bégo-Le-Bagousse+G%22">Bégo-Le-Bagousse G</searchLink>; Sanofi, Gentilly, France.<br /><searchLink fieldCode="AU" term="%22Wang+Z%22">Wang Z</searchLink>; Regeneron Pharmaceuticals Inc, Tarrytown, NY, USA.<br /><searchLink fieldCode="AU" term="%22Noonan+K%22">Noonan K</searchLink>; Sanofi, Cambridge, MA, USA.<br /><searchLink fieldCode="AU" term="%22Bastian+M%22">Bastian M</searchLink>; Sanofi, Frankfurt, Germany. mike.bastian@sanofi.com. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101590450%22">Dermatology and therapy</searchLink> [Dermatol Ther (Heidelb)] 2025 Sep; Vol. 15 (9), pp. 2537-2551. <i>Date of Electronic Publication: </i>2025 Jul 11. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer+Healthcare+Communications%22">Springer Healthcare Communications </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101590450 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Print <i>ISSN: </i>2193-8210 (Print) <i>NLM ISO Abbreviation: </i>Dermatol Ther (Heidelb) <i>Subsets: </i>PubMed not MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=40646412 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1007/s13555-025-01479-y Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 2537 Titles: – TitleFull: Dupilumab versus Lebrikizumab Demonstrates Greater Likelihood of Achieving and Maintaining Improvements in Efficacy Outcomes Using a Placebo-Adjusted Indirect Treatment Comparison. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Ständer S – PersonEntity: Name: NameFull: Pinter A – PersonEntity: Name: NameFull: Hougeir FG – PersonEntity: Name: NameFull: Guyot P – PersonEntity: Name: NameFull: Xu Y – PersonEntity: Name: NameFull: Praestgaard AH – PersonEntity: Name: NameFull: Freemantle N – PersonEntity: Name: NameFull: Rossi AB – PersonEntity: Name: NameFull: Bégo-Le-Bagousse G – PersonEntity: Name: NameFull: Wang Z – PersonEntity: Name: NameFull: Noonan K – PersonEntity: Name: NameFull: Bastian M IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 09 Text: 2025 Sep Type: published Y: 2025 Identifiers: – Type: issn-print Value: 2193-8210 Numbering: – Type: volume Value: 15 – Type: issue Value: 9 Titles: – TitleFull: Dermatology and therapy Type: main |
| ResultId | 1 |